Disease | neutropenia |
Phenotype | C0026946|fungal infections |
Sentences | 8 |
PubMedID- 26392781 | This drug has been approved for the prevention of invasive fungal infections in patients with neutropenia and for the treatment of invasive fungal infections in hematopoietic stem cell transplant recipients with graft-versus-host disease. |
PubMedID- 23730310 | Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in canada. |
PubMedID- 21449626 | Because of the difficult diagnosis and the significant morbidity and mortality of fungal infections in patients with neutropenia, systemic antifungal agents are used as empiric antifungal therapy in patients with febrile neutropenia who are not responding to antibacterial therapy. |
PubMedID- 23975584 | Bacterial infections are common in the early stages of neutropenia, with fungal infections emerging if neutropenia persists beyond 7-10 days. |
PubMedID- 25595699 | It is approved for the prophylaxis of invasive fungal infections in patients with neutropenia or in haematopoietic stem cell transplant recipients undergoing high-dose immunosuppressive therapy for graft-versus-host disease, and for the treatment of fungal infections. |
PubMedID- 21353103 | Objective: this meta-analysis was conducted to estimate the effect of systemic antifungal prophylaxis on the frequency of invasive fungal infections in patients with neutropenia and the mortality associated with these infections. |
PubMedID- 21694893 | Posaconazole has been shown to be more effective than fluconazole or itraconazole for prevention of invasive fungal infections in patients with neutropenia from chemotherapy, leukemia, or myelodysplastic syndrome. |
PubMedID- 23128811 | Donor granulocyte transfusion is one treatment option for haemato-oncology patients with severe neutropenia complicated by bacterial/fungal infections unresponsive to standard antibiotic/antifungal treatment. |
Page: 1